<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585712</url>
  </required_header>
  <id_info>
    <org_study_id>151042-002</org_study_id>
    <nct_id>NCT03585712</nct_id>
  </id_info>
  <brief_title>Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill</brief_title>
  <official_title>A Prospective, Multi-center, Randomized, Cross-over Study to Assess the Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRA Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HRA Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Norgestrel 75 mcg is a progestin-only pill (POP), which is a kind of oral birth control pill.&#xD;
&#xD;
      To be effective in preventing pregnancy, this kind of birth control pill is supposed to be&#xD;
      taken every day at the same time, without delaying the intake for more than 3 hours.&#xD;
&#xD;
      This study aims to find out if taking the pill 6 hours late or not taking it for one day will&#xD;
      affect the way it works.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an exploratory, prospective, multi-center, randomized, cross-over study to&#xD;
      assess the effect of norgestrel 75 mcg on cervical mucus and ovarian activity during reported&#xD;
      perfect daily use, after a delayed intake of 6 hours and after a missed pill.&#xD;
&#xD;
      After a screening period up to one month, depending on the menstrual cycle of the subject,&#xD;
      the subjects will take norgestrel 75 mcg for three 28-day treatment periods, every day at the&#xD;
      same time except for one day in the middle of treatment period 2 and treatment period 3 where&#xD;
      they will either take it 6 hours late or not take it.&#xD;
&#xD;
      In week 5 (1st visit of treatment period 2), they will be randomized to 2 sequences, either 6&#xD;
      hours delayed intake in treatment period 2 and missed pill in treatment period 3 or the&#xD;
      opposite.&#xD;
&#xD;
      After the end of treatment period 3, a follow-up up to 12 days may be required to follow&#xD;
      ovarian activities.&#xD;
&#xD;
      Subjects will have visits twice a week and sometimes more often to assess the effects of the&#xD;
      pill on:&#xD;
&#xD;
        -  cervical mucus properties by a cervical mucus sampling&#xD;
&#xD;
        -  ovarian activity by a vaginal ultrasound (TVUS)&#xD;
&#xD;
        -  reproductive hormones levels by a blood sample (Progesterone (P4), Estradiol (E2),&#xD;
           Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH))&#xD;
&#xD;
        -  plasma drug level by a blood sample&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Actual">April 7, 2020</completion_date>
  <primary_completion_date type="Actual">April 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Delayed Intake or Missed Pill on Cervical Mucus Score (CMS)</measure>
    <time_frame>Day 41 +/- 3 day to Day 43 +/3 days and Day 69 +/- 3 days to Day 71 +/-3 days</time_frame>
    <description>Difference in Cervical Mucus Score between baseline (as Day 41 or Day 69) and delayed (Day 42 and Day 70) or missed pill (Day 43 or day 71)&#xD;
The Insler cervical mucus score (0-12) is the sum of 4 subscores:&#xD;
viscosity from 0 (thick, highly viscous) to 3 (watery,minimally viscous)&#xD;
ferning from 0 (no crystallization) to 3 (tertiary and quaternary stem ferning)&#xD;
spinnbarkeit from 0 (&lt;1 cm) to 3 (&gt;= 9 cm)&#xD;
rank for cells from 0 (&gt;20 cells per High Power Field or &gt;1000 cells per μL) to 3 (0 cell)&#xD;
A score &lt;5 is considered as a protective score while a score &gt;9 is considered as a non protective score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Protective Effect of Cervical Mucus After a 6h Delayed or a Missed Pill</measure>
    <time_frame>Day 41 +/- 3 day to Day 43 +/3 days and Day 69 +/- 3 days to Day 71 +/-3 days</time_frame>
    <description>Subjects are classified according to the risk of losing cervical mucus protection after a 6h delayed or a missed pill, on the day of the infringement and on the day after A cervical mucus score (CMS) &lt;5 is considered as a protective score&#xD;
Full protection: CMS stay &lt;5 after both a delayed or a missed pill, on the day of infringement and on the day after.&#xD;
Absence of risk increase: CMS stay &lt;5 on the day of infringement and on the day after.&#xD;
Transient risk increase: CMS increase &gt;=5 on the day of infringement but go back to &lt;5 on the day after.&#xD;
Prolonged risk increase: CMS increase &gt;=5 on the day of infringement and stay &gt;=5 on the day after.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian Status (OS)</measure>
    <time_frame>From Day 1 to Day 84 (if no follow-up) or up to Day 90 (if follow-up)</time_frame>
    <description>Ovarian Status (OS) defined as:&#xD;
OSq = quiescence defined as an Ovarian Activity Score (OAS) =&lt; 3&#xD;
OSa = active defined as OAS = 4 or 5&#xD;
OSalp = ovulation with abnormal luteal phase defined as OAS = 6 at only one visit&#xD;
OSnlp = ovulation with normal luteal phase as defined as OAS = 6 at two consecutive visits or OAS = 7&#xD;
Ovarian Activity Score between 1 and 7:&#xD;
1= No ovarian activity&#xD;
2= Potential activity&#xD;
3= Non-active follicle like structure&#xD;
4= Active follicle like structure&#xD;
5= Postovulatory, low progesterone level&#xD;
6= Postovulatory, intermediate progesterone level&#xD;
7= Postovulatory, high progesterone level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical Mucus Protection</measure>
    <time_frame>From Day 1 to Day 84</time_frame>
    <description>Higher Cervical Mucus Score (CMS) in:&#xD;
Treatment Period 1 (Reported Perfect Use Period)&#xD;
Delayed pill period: Treatment Period 2 for Arm A and Treatment Period 3 for Arm B&#xD;
Missed pill period: Treatment Period 3 for Arm A and Treatment Period 2 for Arm B&#xD;
A score =&lt; 4 is considered as a protective score and a score &gt;= 9 is considered as a non protective score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conception Protection Risk</measure>
    <time_frame>Day 1 to Day 84 (up to Day 90 if follow-up)</time_frame>
    <description>Binary analysis of whether a subject is at risk of conception based only on their ovarian status (OS) and cervical mucus score (CMS) the days before ovulation:&#xD;
Are considered protected, subjects with OSq, OSa OR CMS =&lt;4 Are considered at risk, subjects with OSalp or OSnlp AND CMS &gt;=5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conception Protection Level</measure>
    <time_frame>Day 1 to Day 84 (up to Day 90 if follow-up)</time_frame>
    <description>Ternary analysis of the level of protection from conception of subjects, based only on the ovarian status (OS) and cervical mucus score (CMS) the days before ovulation:&#xD;
Minimum protection or unlikely to be protected: OSnlp and CMS ≥ 9&#xD;
Medium protection or likely to be protected: OSnlp and CMS comprised between 5 and 8 or OSalp and CMS ≥ 5&#xD;
Maximum protection or highly likely to be protected: OSq or OSa or a CMS ≤ 4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Arm A: Delayed then Missed Pill</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment period 2, Day 42 +/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: missed pill of Norgestrel 75 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Missed then Delayed Pill</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment period 2, Day 42 +/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norgestrel 0.075 mg</intervention_name>
    <description>Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3</description>
    <arm_group_label>Arm A: Delayed then Missed Pill</arm_group_label>
    <arm_group_label>Arm B: Missed then Delayed Pill</arm_group_label>
    <other_name>Norgestrel 75 mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women in good overall health with no chronic medical conditions that result in&#xD;
             periodic exacerbations that require significant medical care&#xD;
&#xD;
          -  Women between 18 and 35 years inclusive at the screening visit&#xD;
&#xD;
          -  BMI&lt; 32 kg/m²&#xD;
&#xD;
          -  Regular menstrual cycles between 21 and 35 days when not using hormonal contraception.&#xD;
&#xD;
               -  Subjects postpartum or post-abortal must have one normal menstrual cycle (2&#xD;
                  menses) prior to enrollment.&#xD;
&#xD;
               -  Subjects previously using Intra-Uterine Device (IUD) or taking hormonal&#xD;
                  contraception (or any other hormonal treatment, except an injectable treatment)&#xD;
                  need to have at least one menstrual cycle (2 menses) without the treatment before&#xD;
                  screening.&#xD;
&#xD;
               -  Subject previously using an injectable (DMPA), must have had their last injection&#xD;
                  at least 9 months before screening.&#xD;
&#xD;
          -  Women not at risk of pregnancy: not sexually active, or willing to protect all acts of&#xD;
             intercourse with condoms, or have a sterile partner or have undergone previous tubal&#xD;
             ligation (including validated Essure), or be in a same sex relationship.&#xD;
&#xD;
          -  Women able to give informed consent form to participate in the study and in the&#xD;
             opinion of the investigator able to follow all study requirements, use the study&#xD;
             medication and record the requested information appropriately&#xD;
&#xD;
          -  Intact uterus and both ovaries&#xD;
&#xD;
          -  At least one progesterone concentration &gt; 3 ng/mL (&gt;10 nmol/L) during the luteal phase&#xD;
             of the screening period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant as confirmed by positive high-sensitivity urine pregnancy test at enrollment&#xD;
             visit&#xD;
&#xD;
          -  Trying to conceive or desire to conceive in the next 3 months&#xD;
&#xD;
          -  Currently breastfeeding, or within the last 2 months&#xD;
&#xD;
          -  Known Polycystic Ovarian Syndrome (PCOS)&#xD;
&#xD;
          -  Cancer (or past history of any carcinoma or sarcoma)&#xD;
&#xD;
          -  Known abnormal thyroid status, if in clinical judgment of the investigator it cannot&#xD;
             be controlled during the study&#xD;
&#xD;
          -  Known hypersensitivity to the ingredients of the test active substances or its&#xD;
             excipients&#xD;
&#xD;
          -  Current acute liver disease and/or benign liver tumors&#xD;
&#xD;
          -  Have vaginal or cervical infection including clinical evidence of bacterial vaginosis&#xD;
&#xD;
          -  Evidence of abnormal cervical lesion&#xD;
&#xD;
          -  History of excisional or ablative treatment procedure on cervix (ie. Loop&#xD;
             Electrosurgical Excision Procedure (LEEP), Cryotherapy, Cold Knife Cone)&#xD;
&#xD;
          -  Undiagnosed abnormal uterine bleeding&#xD;
&#xD;
          -  Prior malabsorptive-type bariatric surgery&#xD;
&#xD;
          -  Known or suspected alcoholism or illicit drug abuse&#xD;
&#xD;
          -  Use of any hormonal contraception or IUD other than the study medication during the&#xD;
             study (including ulipristal acetate for emergency contraception in the past 5 days)&#xD;
&#xD;
          -  Use of any medications that can interfere with the metabolism of progestin-based&#xD;
             contraceptives (e.g CYP3A4 enzymes inducers or inhibitors, etc)&#xD;
&#xD;
          -  Unstable diabetes mellitus&#xD;
&#xD;
          -  Current participation in any other trial of an investigational medicine or&#xD;
             participation in the past two months (or within 5 elimination half-lives for chemical&#xD;
             entities or 2 elimination half-lives for antibodies, whichever is the longer) before&#xD;
             screening&#xD;
&#xD;
          -  Abnormalities in laboratory results or TVUS performed at screening visit recognized as&#xD;
             clinically significant by the investigator&#xD;
&#xD;
          -  Conditions not suitable for frequent TVUS examinations, (e.g. virgo intacta)&#xD;
&#xD;
          -  In custody or submitted to an institution due to a judicial order&#xD;
&#xD;
          -  Relative or household member of the investigator's or sponsor's staff&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Edelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Sciences University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Creinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://apps.who.int/iris/bitstream/handle/10665/44261/9789241547789_eng.pdf;jsessionid=9C2792C737959457E7FC8947BA13D21E?sequence=1://</url>
    <description>World Health Organization Laboratory Manual for the Examination and Processing of Human Semen. Fifth edition 2010</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <results_first_submitted>April 6, 2021</results_first_submitted>
  <results_first_submitted_qc>June 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2021</results_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Birth Control</keyword>
  <keyword>Progestin Only Pill</keyword>
  <keyword>Estrogen Free Pill</keyword>
  <keyword>Norgestrel</keyword>
  <keyword>Oral Contraception</keyword>
  <keyword>Female Contraception</keyword>
  <keyword>Cervical Mucus</keyword>
  <keyword>Ovarian Activity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03585712/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03585712/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrolled subjects were randomized at the first visit of week 5 (first week of treatment period 2) in Arm A or B.&#xD;
All subjects received the same treatment during the first four weeks of treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Period 1: All Enrolled Subjects</title>
          <description>Subjects were enrolled in treatment period 1 without being assigned an arm (Arm A or Arm B) until week 5.&#xD;
Subjects took norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3</description>
        </group>
        <group group_id="P2">
          <title>Arm A: Delayed Then Missed Pill</title>
          <description>Treatment period 2, visit Day 42+/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, visit Day 70+/- 3 days: missed pill of Norgestrel 75 mcg&#xD;
Subjects took norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3</description>
        </group>
        <group group_id="P3">
          <title>Arm B: Missed Then Delayed Pill</title>
          <description>Treatment period 2, visit Day 42+/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, visit Day 70+/-3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg&#xD;
Subjects took norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="0">Randomization in Treatment Period 2</participants>
                <participants group_id="P3" count="0">Randomization in Treatment Period 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Periods 2 and 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Subjects having completed Treatment Period 1 randomized in Arm A or Arm B</participants>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects enrolled in the study</population>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled Subjects</title>
          <description>All subjects enrolled in the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.96" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Delayed Intake or Missed Pill on Cervical Mucus Score (CMS)</title>
        <description>Difference in Cervical Mucus Score between baseline (as Day 41 or Day 69) and delayed (Day 42 and Day 70) or missed pill (Day 43 or day 71)&#xD;
The Insler cervical mucus score (0-12) is the sum of 4 subscores:&#xD;
viscosity from 0 (thick, highly viscous) to 3 (watery,minimally viscous)&#xD;
ferning from 0 (no crystallization) to 3 (tertiary and quaternary stem ferning)&#xD;
spinnbarkeit from 0 (&lt;1 cm) to 3 (&gt;= 9 cm)&#xD;
rank for cells from 0 (&gt;20 cells per High Power Field or &gt;1000 cells per μL) to 3 (0 cell)&#xD;
A score &lt;5 is considered as a protective score while a score &gt;9 is considered as a non protective score</description>
        <time_frame>Day 41 +/- 3 day to Day 43 +/3 days and Day 69 +/- 3 days to Day 71 +/-3 days</time_frame>
        <population>Full Analysis Set for Primary endpoint: Subjects who had cervical mucus score for either D41-D43 or D69-71</population>
        <group_list>
          <group group_id="O1">
            <title>Delayed Pill Intake</title>
            <description>All the subjects of Arm A during treatment period 2 and all the subjects of Arm B during treatment period 3&#xD;
Norgestrel 0.075 mg: Subjects took norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for one specific day (Day 42 +/3 days) during treatment period 2 or treatment period 3 (Day 70 +/3 days) where they delayed their pill intake of 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Missed Pill Intake</title>
            <description>All the subjects of Arm B during treatment period 2 and all the subjects of Arm A during treatment period 3&#xD;
Norgestrel 0.075 mg: Subjects took norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for one specific day (Day 42 +/3 days) during treatment period 2 or treatment period 3 (Day 70 +/3 days) where they missed their pill</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Delayed Intake or Missed Pill on Cervical Mucus Score (CMS)</title>
          <description>Difference in Cervical Mucus Score between baseline (as Day 41 or Day 69) and delayed (Day 42 and Day 70) or missed pill (Day 43 or day 71)&#xD;
The Insler cervical mucus score (0-12) is the sum of 4 subscores:&#xD;
viscosity from 0 (thick, highly viscous) to 3 (watery,minimally viscous)&#xD;
ferning from 0 (no crystallization) to 3 (tertiary and quaternary stem ferning)&#xD;
spinnbarkeit from 0 (&lt;1 cm) to 3 (&gt;= 9 cm)&#xD;
rank for cells from 0 (&gt;20 cells per High Power Field or &gt;1000 cells per μL) to 3 (0 cell)&#xD;
A score &lt;5 is considered as a protective score while a score &gt;9 is considered as a non protective score</description>
          <population>Full Analysis Set for Primary endpoint: Subjects who had cervical mucus score for either D41-D43 or D69-71</population>
          <units>changes in scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Difference in CMs after a 3-hour late pill</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in CMs after a 6-hour late pill</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in CMs after a 24-hour late pill (missed pill)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference in CMS between 3h delay and next pill 18h later</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed model for repeated measures using as response delta to Day41, delta to Day42, delta to Day70 and delta to Day71.&#xD;
Covariates: period, intervention (missed pill or delayed pill), sequence of intervention (missed pill then delayed pill and vice versa), time and subject.&#xD;
Subject as random effect + time repeated effect within each combination subject* period</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Is the overall mean change from baseline different from zero? Or did the infringement of schedule regardless the type of infringement lead to a change in mucus score?</non_inferiority_desc>
            <p_value>0.26</p_value>
            <p_value_desc>P value from model testing intercept (does infringement change mucus score?) P-value from a repeated measures mixed model with the period, intervention, sequence and time (visit) as covariates. P-values ≤0.050 are considered significant</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Protective Effect of Cervical Mucus After a 6h Delayed or a Missed Pill</title>
        <description>Subjects are classified according to the risk of losing cervical mucus protection after a 6h delayed or a missed pill, on the day of the infringement and on the day after A cervical mucus score (CMS) &lt;5 is considered as a protective score&#xD;
Full protection: CMS stay &lt;5 after both a delayed or a missed pill, on the day of infringement and on the day after.&#xD;
Absence of risk increase: CMS stay &lt;5 on the day of infringement and on the day after.&#xD;
Transient risk increase: CMS increase &gt;=5 on the day of infringement but go back to &lt;5 on the day after.&#xD;
Prolonged risk increase: CMS increase &gt;=5 on the day of infringement and stay &gt;=5 on the day after.</description>
        <time_frame>Day 41 +/- 3 day to Day 43 +/3 days and Day 69 +/- 3 days to Day 71 +/-3 days</time_frame>
        <population>Full Analysis Set for Primary endpoint: Subjects who had cervical mucus score for either D41-D43 or D69-71 and a CMS at Baseline =&lt; 5</population>
        <group_list>
          <group group_id="O1">
            <title>Delayed Pill Intake</title>
            <description>All the subjects of Arm A during treatment period 2 and all the subjects of Arm B during treatment period 3&#xD;
Norgestrel 0.075 mg: Subjects took norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for one specific day (Day 42 +/3 days) during treatment period 2 or treatment period 3 (Day 70 +/3 days) where they delayed their pill intake of 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Missed Pill Intake</title>
            <description>All the subjects of Arm B during treatment period 2 and all the subjects of Arm A during treatment period 3&#xD;
Norgestrel 0.075 mg: Subjects took norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for one specific day (Day 42 +/3 days) during treatment period 2 or treatment period 3 (Day 70 +/3 days) where they missed their pill</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Protective Effect of Cervical Mucus After a 6h Delayed or a Missed Pill</title>
          <description>Subjects are classified according to the risk of losing cervical mucus protection after a 6h delayed or a missed pill, on the day of the infringement and on the day after A cervical mucus score (CMS) &lt;5 is considered as a protective score&#xD;
Full protection: CMS stay &lt;5 after both a delayed or a missed pill, on the day of infringement and on the day after.&#xD;
Absence of risk increase: CMS stay &lt;5 on the day of infringement and on the day after.&#xD;
Transient risk increase: CMS increase &gt;=5 on the day of infringement but go back to &lt;5 on the day after.&#xD;
Prolonged risk increase: CMS increase &gt;=5 on the day of infringement and stay &gt;=5 on the day after.</description>
          <population>Full Analysis Set for Primary endpoint: Subjects who had cervical mucus score for either D41-D43 or D69-71 and a CMS at Baseline =&lt; 5</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Full Protection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of risk increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient risk increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolonged risk increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absence of risk increase</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <p_value_desc>p values &gt; 0.050 (Not Statistically significant)</p_value_desc>
            <method>McNemar</method>
            <method_desc>McNemar test comparing agreement in the missed and delayed periods</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Transient risk increase</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.655</p_value>
            <p_value_desc>p values &gt; 0.050 (Not Statistically significant)</p_value_desc>
            <method>McNemar</method>
            <method_desc>McNemar test comparing agreement in the missed and delayed periods</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Prolonged risk increase</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.317</p_value>
            <p_value_desc>p values &gt; 0.050 (Not Statistically significant)</p_value_desc>
            <method>McNemar</method>
            <method_desc>McNemar test comparing agreement in the missed and delayed periods</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ovarian Status (OS)</title>
        <description>Ovarian Status (OS) defined as:&#xD;
OSq = quiescence defined as an Ovarian Activity Score (OAS) =&lt; 3&#xD;
OSa = active defined as OAS = 4 or 5&#xD;
OSalp = ovulation with abnormal luteal phase defined as OAS = 6 at only one visit&#xD;
OSnlp = ovulation with normal luteal phase as defined as OAS = 6 at two consecutive visits or OAS = 7&#xD;
Ovarian Activity Score between 1 and 7:&#xD;
1= No ovarian activity&#xD;
2= Potential activity&#xD;
3= Non-active follicle like structure&#xD;
4= Active follicle like structure&#xD;
5= Postovulatory, low progesterone level&#xD;
6= Postovulatory, intermediate progesterone level&#xD;
7= Postovulatory, high progesterone level</description>
        <time_frame>From Day 1 to Day 84 (if no follow-up) or up to Day 90 (if follow-up)</time_frame>
        <population>Full Analysis Set - Ovarian Activity: Subjects with an Ovarian Status (OS) for either Treatment Period 2 or Treatment Period 3</population>
        <group_list>
          <group group_id="O1">
            <title>OS: Reported Perfect Use Period (Treatment Period 1)</title>
            <description>Subjects in Treatment Period 1 who also had an Ovarian Status in either Treatment Period 2 or Treatment Period 3</description>
          </group>
          <group group_id="O2">
            <title>OS: Delayed Pill Period</title>
            <description>Subjects with Ovarian Status, of:&#xD;
Arm A in Treatment Period 2&#xD;
Arm B in Treatment Period 3</description>
          </group>
          <group group_id="O3">
            <title>OS: Missed Pill Period</title>
            <description>Subjects with Ovarian Status, of:&#xD;
Arm A in Treatment Period 3&#xD;
Arm B in Treatment Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Ovarian Status (OS)</title>
          <description>Ovarian Status (OS) defined as:&#xD;
OSq = quiescence defined as an Ovarian Activity Score (OAS) =&lt; 3&#xD;
OSa = active defined as OAS = 4 or 5&#xD;
OSalp = ovulation with abnormal luteal phase defined as OAS = 6 at only one visit&#xD;
OSnlp = ovulation with normal luteal phase as defined as OAS = 6 at two consecutive visits or OAS = 7&#xD;
Ovarian Activity Score between 1 and 7:&#xD;
1= No ovarian activity&#xD;
2= Potential activity&#xD;
3= Non-active follicle like structure&#xD;
4= Active follicle like structure&#xD;
5= Postovulatory, low progesterone level&#xD;
6= Postovulatory, intermediate progesterone level&#xD;
7= Postovulatory, high progesterone level</description>
          <population>Full Analysis Set - Ovarian Activity: Subjects with an Ovarian Status (OS) for either Treatment Period 2 or Treatment Period 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>OSq</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OSa</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OSalp</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OSnlp</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A stratified McNemar test (stratification on the site, AGREE option in SAS) was used to compare the distribution of ovarian activity classification in the perfect use period to the delayed and missed pill periods (pairwise vs perfect use). The worst (meaning most risk of ovulation) ovarian activity category in the period was used for the analyses.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Indicates significance at the 0.05 level (p-value ≤ 0.05)</p_value_desc>
            <method>McNemar</method>
            <method_desc>P-value from an exact kappa test comparing agreement of ovarian status vs the reported perfect use period</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A stratified McNemar test (stratification on the site, AGREE option in SAS) was used to compare the distribution of ovarian activity classification in the perfect use period to the delayed and missed pill periods (pairwise vs perfect use). The worst (meaning most risk of ovulation) ovarian activity category in the period was used for the analyses.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Indicates significance at the 0.05 level (p-value ≤ 0.05)</p_value_desc>
            <method>McNemar</method>
            <method_desc>P-value from an exact kappa test comparing agreement of ovarian status vs the reported perfect use period.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cervical Mucus Protection</title>
        <description>Higher Cervical Mucus Score (CMS) in:&#xD;
Treatment Period 1 (Reported Perfect Use Period)&#xD;
Delayed pill period: Treatment Period 2 for Arm A and Treatment Period 3 for Arm B&#xD;
Missed pill period: Treatment Period 3 for Arm A and Treatment Period 2 for Arm B&#xD;
A score =&lt; 4 is considered as a protective score and a score &gt;= 9 is considered as a non protective score</description>
        <time_frame>From Day 1 to Day 84</time_frame>
        <population>Full Analysis Set - Mucus Secondary: Subjects who had cervical mucus scores for at least 7 visits for either Treatment Period 2 or Treatment Period 3</population>
        <group_list>
          <group group_id="O1">
            <title>CMS: Reported Perfect Use Period (Treatment Period 1)</title>
            <description>Subjects in Treatment Period 1 who had at least 7 cervical mucus scores in either Treatment Period 2 or Treatment Period 3</description>
          </group>
          <group group_id="O2">
            <title>CMS: Delayed Pill Period</title>
            <description>Subjects who had at least 7 cervical mucus scores in:&#xD;
Arm A: Treatment Period 2&#xD;
Arm B: Treatment Period 3</description>
          </group>
          <group group_id="O3">
            <title>CMS: Missed Pill Period</title>
            <description>Subjects who had at least 7 cervical mucus scores in:&#xD;
Arm A: Treatment Period 3&#xD;
Arm B: Treatment Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Cervical Mucus Protection</title>
          <description>Higher Cervical Mucus Score (CMS) in:&#xD;
Treatment Period 1 (Reported Perfect Use Period)&#xD;
Delayed pill period: Treatment Period 2 for Arm A and Treatment Period 3 for Arm B&#xD;
Missed pill period: Treatment Period 3 for Arm A and Treatment Period 2 for Arm B&#xD;
A score =&lt; 4 is considered as a protective score and a score &gt;= 9 is considered as a non protective score</description>
          <population>Full Analysis Set - Mucus Secondary: Subjects who had cervical mucus scores for at least 7 visits for either Treatment Period 2 or Treatment Period 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CMS &lt;=4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>CMS between 5 &amp; 8 (inclusive)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>CMS &gt;=9</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified McNemar test (stratification on the site, AGREE option in SAS) to compare the distribution of cervical mucus scores in the perfect use period to the delayed and missed pill periods (pairwise vs perfect use).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>McNemar</method>
            <method_desc>P-value from an exact kappa test comparing agreement of cervical mucus score classification vs the reported perfect use period</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Stratified McNemar test (stratification on the site, AGREE option in SAS) to compare the distribution of cervical mucus scores in the perfect use period to the delayed and missed pill periods (pairwise vs perfect use).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>* Indicates significance at the 0.05 level (p-value ≤ 0.05).</p_value_desc>
            <method>McNemar</method>
            <method_desc>P-value from an exact kappa test comparing agreement of cervical mucus score classification vs the reported perfect use period.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conception Protection Risk</title>
        <description>Binary analysis of whether a subject is at risk of conception based only on their ovarian status (OS) and cervical mucus score (CMS) the days before ovulation:&#xD;
Are considered protected, subjects with OSq, OSa OR CMS =&lt;4 Are considered at risk, subjects with OSalp or OSnlp AND CMS &gt;=5</description>
        <time_frame>Day 1 to Day 84 (up to Day 90 if follow-up)</time_frame>
        <population>Full Analysis Set - Conception: Subjects who had a OS + enough CMS to assess their Conception Protection Risk &amp; Level in either Treatment Period 2 or Treatment Period 3</population>
        <group_list>
          <group group_id="O1">
            <title>CP/R&amp;L: Reported Perfect Use Period (Treatment Period 1)</title>
            <description>Subjects in Treatment Period 1 who had a OS + enough CMS to assess their Conception Protection Risk &amp; Level in either Treatment Period 2 or Treatment Period 3</description>
          </group>
          <group group_id="O2">
            <title>CP/R&amp;L: Delayed Pill Period</title>
            <description>Subjects who had a OS + enough CMS to asses their Conception Protection Risk &amp; Level in:&#xD;
Arm A: Treatment Period 2&#xD;
Arm B: Treatment Period 3</description>
          </group>
          <group group_id="O3">
            <title>CP/R&amp;L: Missed Pill Period</title>
            <description>Subjects who had a OS + enough CMS to assess their Conception Protection Risk &amp; Level in:&#xD;
Arm A: Treatment Period 3&#xD;
Arm B: Treatment Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Conception Protection Risk</title>
          <description>Binary analysis of whether a subject is at risk of conception based only on their ovarian status (OS) and cervical mucus score (CMS) the days before ovulation:&#xD;
Are considered protected, subjects with OSq, OSa OR CMS =&lt;4 Are considered at risk, subjects with OSalp or OSnlp AND CMS &gt;=5</description>
          <population>Full Analysis Set - Conception: Subjects who had a OS + enough CMS to assess their Conception Protection Risk &amp; Level in either Treatment Period 2 or Treatment Period 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Protected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>At risk</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conception Protection Level</title>
        <description>Ternary analysis of the level of protection from conception of subjects, based only on the ovarian status (OS) and cervical mucus score (CMS) the days before ovulation:&#xD;
Minimum protection or unlikely to be protected: OSnlp and CMS ≥ 9&#xD;
Medium protection or likely to be protected: OSnlp and CMS comprised between 5 and 8 or OSalp and CMS ≥ 5&#xD;
Maximum protection or highly likely to be protected: OSq or OSa or a CMS ≤ 4</description>
        <time_frame>Day 1 to Day 84 (up to Day 90 if follow-up)</time_frame>
        <population>Full Analysis Set - Conception: Subjects who had a OS + enough CMS to assess their Conception Protection Risk &amp; Level in either Treatment Period 2 or Treatment Period 3</population>
        <group_list>
          <group group_id="O1">
            <title>CP/R&amp;L: Reported Perfect Use Period (Treatment Period 1)</title>
            <description>Subjects in Treatment Period 1 who had a OS + enough CMS to assess their Conception Protection Risk &amp; Level in either Treatment Period 2 or Treatment Period 3</description>
          </group>
          <group group_id="O2">
            <title>CP/R&amp;L: Delayed Pill Period</title>
            <description>Subjects who had a OS + enough CMS to asses their Conception Protection Risk &amp; Level in:&#xD;
Arm A: Treatment Period 2&#xD;
Arm B: Treatment Period 3</description>
          </group>
          <group group_id="O3">
            <title>CP/R&amp;L: Missed Pill Period</title>
            <description>Subjects who had a OS + enough CMS to assess their Conception Protection Risk &amp; Level in:&#xD;
Arm A: Treatment Period 3&#xD;
Arm B: Treatment Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Conception Protection Level</title>
          <description>Ternary analysis of the level of protection from conception of subjects, based only on the ovarian status (OS) and cervical mucus score (CMS) the days before ovulation:&#xD;
Minimum protection or unlikely to be protected: OSnlp and CMS ≥ 9&#xD;
Medium protection or likely to be protected: OSnlp and CMS comprised between 5 and 8 or OSalp and CMS ≥ 5&#xD;
Maximum protection or highly likely to be protected: OSq or OSa or a CMS ≤ 4</description>
          <population>Full Analysis Set - Conception: Subjects who had a OS + enough CMS to assess their Conception Protection Risk &amp; Level in either Treatment Period 2 or Treatment Period 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Maximum/Highly Likely to be Protected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Medium/Likely to be Protected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimum/Unlikely to be Protected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 to Day 84</time_frame>
      <desc>Systematic Assesment:&#xD;
Adverse Events collected at each visit&#xD;
Hematology, Chemistry, Vital Signs collected at End of Study visit&#xD;
Vaginal Bleedings recorded daily by subjects in a diary</desc>
      <group_list>
        <group group_id="E1">
          <title>All Enrolled Subjects</title>
          <description>All subjects enrolled in the study.&#xD;
The adverse events were reported for all the subjects enrolled in the study for the entire length of the study.&#xD;
The subjects were randomized in their respective arm in week 5. Subjects in Arm A had a 6 hour delayed pill at Day 42 +/- 3 days and a missed pill at Day 70+/- 3 days while subjects in Arm B had a missed pill at Day 70+/- 3 days and a 6 hour delayed pill at Day 42 +/- 3 days.&#xD;
It was considered that the difference in investigational medication intake between the arms would not have an impact on adverse event's frequency, so the adverse events were reported for all subjects enrolled, whatever the arm they were assigned to, and for the entire length of the study.</description>
        </group>
        <group group_id="E2">
          <title>Perfect Use Period</title>
          <description>All the subjects having starting treatment period 1.&#xD;
Affected participants by an adverse event during this treatment period are reported out of the total of subjects having started the treatment period 1.</description>
        </group>
        <group group_id="E3">
          <title>Delayed Pill Intake</title>
          <description>Subjects having started a delayed pill period, meaning treatment period 2 for subjects randomized in week 5 in Arm A, and treatment period 3 for subjects in Arm B&#xD;
Affected participants by an adverse event during this treatment period are reported out of the total of subjects having started this treatment period.</description>
        </group>
        <group group_id="E4">
          <title>Missed Pill Intake</title>
          <description>Subjects having started a missed pill period, meaning treatment period 3 for subjects randomized in week 5 in Arm A, and treatment period 2 for subjects in Arm B&#xD;
Affected participants by an adverse event during this treatment period are reported out of the total of subjects having started this treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <description>Anaphylaxis Reaction with difficulty breathing. Severe. Recovered/Resolved Not Related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spams</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Uterine spasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Agnes Hemon</name_or_title>
      <organization>HRA Pharma</organization>
      <phone>0140337092</phone>
      <email>a.hemon@hra-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

